Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Continuous pazopanib · 1 trial · 1 indication
TTF is the time to permanent treatment discontinuation due to any cause after randomization in each arm
| Arm | Type | Description |
|---|---|---|
| Continuous pazopanib (Arm A) | ACTIVE_COMPARATOR | Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization |
| Intermittent pazopanib (Arm B) | EXPERIMENTAL | Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time. This sequential scheme will be maintained until the patient experiences "on-treatment" progression |
| Name | Type | Description |
|---|---|---|
| Continuous pazopanib (Arm A) | DRUG | Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization |
| Intermittent pazopanib (Arm B) | DRUG | Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time. This sequential scheme will be maintained until the patient experiences "on-treatment" progression |
Inclusion Criteria: * Age ≥ 18 years old, * Histologically confirmed diagnosis of differentiated thyroid cancer (papillary, follicular and poorly differentiated) * Archival tumor sample available. It will be provided for all subjects, for biomarker analysis before and/or during study treatment. * P...
Continuous pazopanib is an investigational small molecule being studied for the treatment of thyroid carcinoma. It is currently in Phase 2 clinical development. The drug is being evaluated in a completed clinical trial that enrolled 168 participants with thyroid carcinoma.
Continuous pazopanib is being developed by GSK plc, a pharmaceutical company traded on the stock exchange under the ticker symbol GSK. The company is conducting clinical research on this drug for the treatment of thyroid carcinoma.
Continuous pazopanib is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for treating thyroid carcinoma.
Continuous pazopanib has one completed clinical trial registered as NCT01813136, titled 'Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma.' This Phase 2 trial enrolled 168 participants with thyroid carcinoma and was conducted in France.
Continuous pazopanib refers to a specific dosing regimen of pazopanib, which is the active drug being studied. The clinical trial NCT01813136 investigates the optimal scheme of administration of pazopanib in thyroid carcinoma, comparing continuous dosing with other schedules.